Crossref
Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2
AME Clinical Trials Review · 2026-06 · 4 · 30-30
DOI: 10.21037/actr-25-125 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Mariem Galuia und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Galuia, M., & Socinski, M. A. (2026). Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2. AME Clinical Trials Review, 4, 30-30. https://doi.org/10.21037/actr-25-125
Vancouver
Galuia M, Socinski MA. Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2. AME Clinical Trials Review. 2026;4:30-30. doi:10.21037/actr-25-125
BibTeX
@article{Galuia2026,
author = {Galuia, Mariem and Socinski, Mark A.},
title = {Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {30--30},
doi = {10.21037/actr-25-125}
}
EUVIMED